tiprankstipranks
Lytix Biopharma AS (DE:6BG)
FRANKFURT:6BG
Germany Market

Lytix Biopharma AS (6BG) Cash flow

0 Followers

Lytix Biopharma AS Cash Flow

DE:6BG's free cash flow for Q4 2022 was kr-26.42M. For the 2022 fiscal year, DE:6BG's free cash flow was decreased by kr-7.36M and operating cash flow was kr-26.42M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
kr -52.10Mkr -52.10Mkr -44.90Mkr -24.35Mkr -36.82M
Investing Cash Flow
kr -50.76Mkr -50.76M---
Financing Cash Flow
kr 133.00Kkr 133.00Kkr 213.73Mkr 40.00Mkr -5.00K
Cash Flow From Discontinued Operation
-----
Other Cash Adjustment Inside Changein Cash
-----
End Cash Position
kr 573.97Mkr 94.55Mkr 197.28Mkr 28.45Mkr 12.80M
Income Tax Paid Supplemental Data
-----
Interest Paid Supplemental Data
-----
Issuance Of Capital Stock
kr 133.00Kkr 133.00Kkr 213.73Mkr 40.00M-
Issuance Of Debt
-----
Repayment Of Debt
----kr -5.00K
Free Cash Flow
kr -52.26Mkr -52.26Mkr -44.90Mkr -24.35Mkr -36.82M
Domestic Sales
-----
Foreign Sales
-----
Currency in NOK

Lytix Biopharma AS Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis